Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c < 7% with no hypoglycaemia and no weight gain over 2years

Gallwitz, B.; Rosenstock, J.; Emser, A.; von Eynatten, M.; Woerle, H-J.

dc.contributor.author	Gallwitz, Baptist
dc.date.accessioned	2013-12-16T09:29:22Z
dc.date.available	2013-12-16T09:29:22Z
dc.date.issued	2013
dc.identifier.issn	1368-5031
dc.identifier.uri	http://hdl.handle.net/10900/39608
dc.language.iso	en	en
dc.publisher	Wiley - Blackwell	de_DE
dc.relation.uri	http://dx.doi.org/10.1111/ijcp.12101	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c < 7% with no hypoglycaemia and no weight gain over 2years	de_DE
dc.type	Article	de_DE
utue.quellen.id	20130911224530_01349	de_DE
utue.publikation.seiten	317-321	de_DE
utue.personen.roh	Gallwitz, B.
utue.personen.roh	Rosenstock, J.
utue.personen.roh	Emser, A.
utue.personen.roh	von Eynatten, M.
utue.personen.roh	Woerle, H-J.
dcterms.isPartOf.ZSTitelID	International Journal of Clinical Practice	de_DE
dcterms.isPartOf.ZS-Issue	4	de_DE
dcterms.isPartOf.ZS-Volume	67	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE